Name: Internal Medicine 2018
End: 1970-01-03
Location: Canada

Breast Pathology 2018 - Breast Pathology & Cancer Congress

Recommended Global Pathology Conferences

USA & Americas

Birth Congress 2019, USA American Pathology 2018, USA Personalized Medicine 2018, USA Internal Medicine 2018, Canada

Europe & UK

Euro Pathology 2019, Netherlands Surgical Pathology 2019, Germany Biopathology 2018, Finland Euro Personalized Medicine 2018, Italy

Asia Pacific & Middle East

Personalized Medicine Congress 2018, Japan Pathology Congress 2018 , Japan LABMEDPATH 2018, UAE Pathology Summit 2018, Thailand

Breast Pathology & Cancer Congress

Breast Pathology 2018

Carcinoma is a term used to describe a cancer that begins in the lining layer of breast. Nearly all breast cancers are carcinomas. Most are the type of carcinoma that starts in glandular tissue, which are called adenocarcinomas. If the carcinoma cells have grown and broken out of the ducts or lobules, it is called invasive or infiltrating carcinoma. In an invasive carcinoma, the tumor cells can spread (metastasize) to other parts of your body.

Pathologist is a specialized doctor who studies biopsied sample under microscope and gives a detailed report for diagnosis.

Breast Pathology and cancer congress created a platform for Pathologist, Researchers, Gynecologists, Oncologist, Radiation Oncologist, Palliative Medicine, Primary Care Providers, Plastic Surgeons, Surgeons, Women’s Healthcare professors, epidemiologists, Breast cancer Nurses, Patients, Councillors & who all are the part of Brest Pathology; to pool the knowledge on current trends of Brest pathology diagnosis and Treatment. Breast Pathology 2018 came up with a theme “Understanding current Research to obtain best results in Breast Pathology”

Important Links -

Fast Facts about Breast Cancer

Annually in United States, more than 200,000 women get breast cancer and more than 40,000 women die from the disease. Men may also experience the same, but it is not very common. Less than 1% of breast cancers occur in men.

Most often, breast cancer is observed in women at the age of 50 or more, but breast cancer also seen in younger women. Around 10% of new cases of breast cancer in the United States are found in women younger than 45 years of age.

Breast Pathology Sessions

Track 1 : Breast Cancer Pathology

There are trillions of cells in the body. These cells have regulated cell cycle that controls their growth, maturity, division and death. During childhood normal cells replicates faster to allow the person to grow. Once adulthood is reached the cells divide to replace worn-out cells and to repair injuries. This cell division and growth is controlled by the cellular blue print or DNA and genes that lie within the cell’s nucleus. Cancer initiate when cells in a part of the body start to grow out of control. All types of cancer, irrespective of their origin, occur due to this uncontrollable growth of cells that leads to formation of tumours and lesions. These cells have longer life spans and instead of dying continue to grow and form new, abnormal cells. Cancer cells can also invade other tissues. This property is called metastasis. Cancer cells grow into tumours that are supplied to blood vessels. This is called angiogenesis. Damage to the DNA and genetic mutations can also lead to breast cancer have been experimentally linked to estrogenic exposure. Some individuals inherit defects in the DNA and genes like the BRCA1, BRCA2 and P53 among others. Those with a family history of ovarian or breast cancer thus are at an increased risk of breast cancer.

Related Conferences: 2^nd International Congress on Contemporary Issues in Women Cancers and Gynaecologic Oncology Aug 28-29, 2017 London, UK; 2^nd International Conference on Antimicrobial Agents and Chemotherapy October 19-20, 2017 Atlanta, Georgia, USA; 14^thWorld Cancer & Anti- Cancer Therapy Convention November 21-23, 2016 Dubai, UAE; 13^th International Conference on Surgical Pathology & Practice March 27-28, 2017 Madrid, Spain ; 9^th Global Pathologists Congress December 05-06, 2016 Madrid, Spain; 3^rd International Conference on Cytopathology & Histopathology June 22-23, 2017 Philadelphia, USA; 15^th World Congress on Cancer Therapy, Biomarkers & Clinical Research December 05-07, 2016 Philadelphia, Pennsylvania, USA; 15^th World Congress on Cancer Therapy (977^th Annual Conference) December 05-07, 2016 Philadelphia, Pennsylvania, USA.

Track 2: Breast Pathology Diagnosis

The involvement of pathologists in the management of breast disease divided into four main areas: Diagnosis, Assessment of adequacy of treatment and prognosis, effective communication and research. Biopsy is removal of breast tissue for examination by a pathologist. Mammography , is useful for finding early changes in the breast. Breast ultrasound scans Ultrasound scans use sound waves to make a picture of the inside of the body.

Related Conferences: Global Summit on Oncology & Cancer May 25-27, 2017 Osaka, Japan; 9^th International Conference and Expo on Molecular & Cancer Biomarkers August 23-24, 2017 Birmingham, UK; Medical Expo on Cancer Drugs and Therapeutics Sep 11-13, 2017 Paris, France; International Conference on Gastrointestinal Cancer and Therapeutics October 16-18, 2017 Baltimore, USA; World Digital Pathology & Pathologists Congress December 05-06, 2016 Madrid, Spain; International Congress on Epigenetics & Chromatin; Global Summit on Melanoma & Carcinoma July 14-15, 2016 Brisbane, Australia; 13^thInternational Conference on Surgical Pathology & Practice March 27-28, 2017 Madrid, Spain; International Conference on Cancer Biology R&D and Market June 21 - 22, 2017 Philadelphia, USA.

Track 3: Further Tests for Breast Cancer

In Breast cancer Diagnosis, If tests show that you have breast cancer you will need to have further tests. The tests check the size of the cancer and whether there is any spread to nearby lymph nodes or to other parts of the body. This tells the doctor the stages of cancer. The stage is important because it helps your doctor to decide on the best treatment for you. Most women have blood tests, MRI scan, Lymph node Ultrasound scan and some have a chest X-ray. These may be done as part of standard preparation before surgery.

Track 4:Breast Pathology Treatment

In cancer care, doctors specializing in different areas of cancer treatment—such as surgery, radiation oncology, and medical oncology. Cancer care teams also include a variety of other health care professionals, including physician assistants, oncology nurses, social workers, pharmacists, counsellors, nutritionists, and others. The biology and behaviour of a breast cancer affects the treatment plan. Some tumours are small but grow fast, while others are large and grow slowly. Treatment options and recommendations are very personalized and depend on several factors, including: stage of tumour, tumour subtypes, genomic maker, patient age, and patient menopausal status, mutations in inherited breast cancer genes, such as BRCA1 or BRCA2. For both DCIS and early-stage invasive breast cancer, doctors generally perform surgery to remove the tumour. For larger cancers, or those that are growing more quickly, doctors may recommend systemic treatment with chemotherapy or hormonal therapy before surgery, called neoadjuvant therapy.

Track 5:Recurrent Breast Cancer

The cancer does return after treatment for early-stage disease, it is called recurrent cancer. When breast cancer recurs, it may come back in the following parts of the body, same place as the original cancer, chest wall, lymph node, bones, lungs, liver and brain. A local or regional recurrence is manageable and may be curable for women with a local recurrence in the breast after initial treatment with lumpectomy and adjuvant radiation therapy, the recommended treatment is mastectomy. Usually the cancer is completely removed with this treatment. For women with a local or regional recurrence in the chest wall after an initial mastectomy, surgical removal of the recurrence followed by radiation therapy to the chest wall and lymph nodes is the recommended treatment. However, if radiation therapy has already been given for the initial cancer, this may not be an option. Radiation therapy cannot usually be given at full dose to the same area more than once. For women with a local or regional recurrence in the chest wall after an initial mastectomy, surgical removal of the recurrence followed by radiation therapy to the chest wall and lymph nodes is the recommended treatment.

Track 6:Case study and Case Report on Breast Pathology

In medicine, a case report contains detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case report usually describes an unusual or novel occurrence. Case reports are an unexpected association between diseases or symptoms. It may results in finding the shed new light on the possible pathogenesis of a disease or an adverse effect.it may contour Unique or rare features of a disease, unique therapeutic approaches.

Track 7:Breast Pathology and Surgery

Mastectomy is the surgical removal of the entire breast. Some women have the option of mastectomy or lumpectomy (also called breast conserving surgery) plus radiation therapy. Other women can only have mastectomy. Some women have a very high risk of breast cancer due to an inherited gene mutation. These women may have one or both breasts removed to try to prevent breast cancer called ( prophylactic mastectomy).A woman at very high risk who has cancer in one breast may have her healthy breast removed to try to prevent breast cancer in the healthy breast (contralateral prophylactic mastectomy)A woman at increased risk who does not have breast cancer, may have both breasts removed to try to prevent breast cancer (bilateral prophylactic mastectomy).

Track 8: Breast Pathology and Benign Tumours

Non-cancerous breast conditions are most common and most women have them. In fact, most breast changes that are tested turn out to be benign. Benign is another word for non-cancerous. Benign breast conditions are not life-threatening. Benign conditions and breast cancer has many of the same symptoms. So it can be hard to tell the difference from just symptoms alone. Some breast changes may not cause any symptoms and may be found during a mammogram. But sometimes they can cause symptoms that bother. Benign breast tumours may hurt, but they aren’t dangerous and don’t spread from the breast to other organs. Still, some benign breast conditions, such as papilloma’s and atypical hyperplasia, are important to know about because women with them have a higher risk of developing breast cancer. A biopsy is the only way to find out if a lump is benign or cancer. If a benign tumour is large, it may change the breast’s size and shape. If it’s growing into the tissue of the milk ducts, it may cause an abnormal discharge from the nipple. Depending on the type, size, and number of benign tumours, surgery to recommended.

Track 9: Usual Epithelial Hyperplasia (UEH)

The Separation of epithelial proliferative lesions and differentiation between usual epithelial hyperplasia. And atypical ductal hyperplasia (ADH) is the most common problems encountered. Intra duct benign epithelial proliferation, Epithelial and myoepithelial cells proliferate together. Therefore mixed pattern seen on CK 5/6 or P63 immunostaining. In this condition Streaming pattern usually seen and Peripheral slit-like spaces within ducts is present, Cells are smaller in size, more crowded and overlapping than in atypical proliferations or carcinoma in Situ . Atypical hyperplasia is of three types Atypical Ductal Hyperplasia (ADH): Columnar Cell Change with atypia, Atypical Lobular Hyperplasia (ALH). ADH is important because it carries a 4-5 times relative risk of breast cancer at 10-15 yrs. post biopsy. It causes difficulty to diagnostic pathologists - inconsistency in diagnosis is common. It lies closest morphologically to low grade DCIS - it is not a high grade lesion.

Track 10: Breast Pathology and Malignant Tumours

"Cancer" is used as a generic term to cover the whole range of malignant disease of the breast. This area inevitably constitutes the main focus of study of breast disease as from a clinical point of view. Malignant tumours are cancerous and aggressive because they invade and damage surrounding tissue. When a tumour is suspected to be malignant, the doctor will perform a biopsy to determine the severity or aggressiveness of the tumour. CARCINOMA IN SITU is a type of malignant cancer and also known as pre-invasive carcinoma.it is confined with ducts or lobules this is Immunostains very helpful in diagnosis.

Track11: Less Common Types of Breast Cancer

Research has developed ways of grouping breast cancers into different types. They sometimes call rarer breast cancers special type and the more common breast cancers no special type. More than 90% of breast cancers are invasive carcinoma and 10% are rare types of cancers. The rare types of breast cancers are, medullary breast cancer About 5 out of 100 breast cancers (5%) are medullary breast cancers. The cancer cells tend to be bigger than other breast cancer cells. Mucinous (mucoid or colloid) breast cancers about 2 in 100 breast cancers (2%) are mucinous breast cancers. This type of cancer tends to be slower growing than other types of breast cancers and is less likely to spread to the lymph nodes. Tubular breast cancer is called tubular because the cells look like tubes when seen under a microscope. Only about 1 in 100 breast cancers (1%) are tubular cancers.

Track 12: Breast Pathology and Immunohistochemistry

Immunohistochemistry has an important role in the pathology of breast disease, as well as in other benign or malignant tumours. Overall, immunotherapy holds several key advantages over conventional chemotherapeutic and targeted treatments directed at the tumour itself. First, immunotherapy generally results in fewer side effects, enabling it to be administered for longer periods of time and/or in combination with other agents without added toxicity. The principal function of immunohistochemistry of breast pathology is: Solving common diagnostic dilemmas e.g., Benign/malignant, Epithelial proliferations, in situ v micro invasion. Tumour typing and confirming diagnoses, such as: Tumour typing, subtle foci of invasion, Status of margins, Lymph node metastases, demonstrating epithelial cells in necrotic material. For confirmation of this diagnosis most frequently used immunostains in breast pathology are: Myoepithelial markers - CK 5/6; P63, Lobular v Ductal - E Cadherin, Receptors - ER; PGR and Her2.

Track 13: Breast Cancer and Genetics

The two most common genetic risk factors for breast cancer are the BRCA1 & 2 genes.BRCA1 & BRCA2 Approximately 5% of all breast cancers are caused by a recognised specific genetic predisposition due to germ line mutations of one of two different genes: BRCA1 located on Chromosome 17q, BRCA2 located on Chromosome 13q. BRCA1 mutations also predispose to carcinoma of the ovary and possibly carcinoma of the Fallopian tube. Mutations of this gene are particularly common in Ashkenazy Jews (2%). The risk of developing breast cancer among carriers is around 55% by age 70. BRCA2: The product of BRCA2 is involved in controlling gene function and DNA repair. Gene function involves in transcriptional activation and completion of cell division by cytokinesis. Majority of BRCA2-associated tumours are invasive ductal, no special-type tumours.

Track 14: Breast Pathology and Microcalcification

Malignant micro calcification involves, DCIS and LCIS. Calcification in DCIS may occur with any grade. Finer calcs associated with low grade DCIS, Coarse luminal calcs associated with comedo DCIS and Periductal stromal calcification may be seen alone or as well. LCIS: Florid LCIS & calcs, the uncommon variant of LCIS is commonly accompanied by comedo necrosis and coarse calcification. It may easily be mistaken for DCIS for this reason. The prognosis and management of this lesion if an isolated finding is unclear.

Track 15: Breast Cancer Grading and Staging

In Grading of Breast Cancer Histological grade provides important prognostic and management information. The internationally accepted system is that defined by Elston and Ellis1. Grading is Assess by evaluating acinar formation, nuclear size/pleomorphism and mitotic activity. The Nuclear evaluation is the most subjective and can lead to inconsistency. Although originally designed for grading NST tumours it is recommended that it is applied to all cancers. An attempt should be made to grade the pre-operative core biopsy as there is acceptable concordance with excision grade. Staging: Stage is usually expressed as a number on a scale of 0 through IV — with stage 0 describing non-invasive cancers that remain within their original location and stage IV describing invasive cancers that have spread outside the breast to other parts of the body.

Track 16: Special Types of Carcinoma

20% of breast carcinomas are of special type and the majority of these are lobular carcinomas. Tubular and mucinous carcinomas occur next most frequently and thereafter the remaining special types are seen infrequently. In order to make a diagnosis of a special type of carcinoma >90% of the tumour is required to show the particular pattern in question. Special types of carcinoma should be distinguished from mixed carcinomas where the special type areas occupy between 50 and 90% of the tumour area with the remaining area being usually of no special type.

Track 17:Breast Cancer and Pregnancy

Breast cancer is found in about 1 in every 3,000 pregnant women. Breast cancer is the most common type of cancer found during http://www.omicsgroup.org/journals/pregnancy-and-child-health.phppregnancy, while breastfeeding, or within the first year of delivery. You may hear this called gestational breast cancer or pregnancy-associated breast cancer (PABC). When a pregnant woman develops breast cancer, it’s often diagnosed at a later stage than it would be if the woman were not pregnant. It’s also more likely to have spread to the lymph nodes. This is partly because hormone changes during pregnancy. Another reason it may be hard to find breast cancers early during pregnancy is that screening for breast cancer is often delayed until after the pregnancy is over. Pregnancy and breast feeding can also make breast tissue denser.

Track 18: Breast Cancer Prevention

Women may prevent their risk of breast cancer by maintaining a healthy weight, drinking less alcohol, being physically active and breastfeeding their children. Avoiding risk factors and increasing protective factors may help prevent cancer. The following are risk factors for breast cancer: Older age, A personal history of breast cancer or benign (no cancer) breast disease, A family history of breast cancer, Inherited gene changes, Dense breasts, Exposure of breast tissue to oestrogen, made in the body, Taking hormone, therapy for symptoms of menopause, Radiation therapy to the breast or chest, Obesity, Drinking alcohol, Being white.

Market Projection

The breast cancer treatment market was valued at USD 12,306.3 Mn in 2017, and is expected to reach USD 18,801.3 Mn by 2025, expanding at a CAGR of 7.6% from 2017 - 2025.

Market Projection on Breast Cancer Therapeutics

Breast Pathology is a Major Field in modern medical Practice and Diagnosis. Current year estimates for breast cancer are The American Cancer Society's and estimates for breast cancer in the United States for 2016 and reported that About 246,660 new cases of invasive breast cancer will be diagnosed in women. About 61,000 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is non-invasive and is the earliest form of breast cancer). About 40,450 women will die from breast cancer.

Conference Highlights

Breast Cancer Pathology
Breast Pathology Diagnosis
Breast Pathology Treatment
Breast Pathology Case Report
Breast Pathology and Surgery
Breast Pathology and Benign Tumours
Breast Pathology and Malignant Tumours
Breast Pathology and Micro Calcification
Special Type of Carcinoma
Breast Pathology and Immunochemistry
Breast Cancer and Genetics
Breast Cancer and Pregnancy
Breast Pathology and Prevention

Why Vancouver!

Depending on the Compound annual growth rate of Breast Pathology market, North America stands in first rank next come Europe and Asia so the Breast Pathology 2018 is going to be held in Vancouver, Canada. Vancouver is Famous for Its Beauty. One of the most famous things about Vancouver is its physical beauty. Surrounded by snowcapped mountains and deep blue sea, Vancouver is gorgeous; when the sun is shining, it's truly a sight to behold It's a global centre for business, finance, arts and culture and is consistently ranked one of the world's most liveable cities. The University of British Columbia has assembled one of the strongest research and teaching faculties in North America, presenting top students at all levels with an intellectual environment unmatched in breadth and depth on any other Canadian campus. the research division of Vancouver is also home to one of the world's leading research programs with multidisciplinary experts in the fields of oncology, cardiology, transplantation, immunology and autoimmunity, infectious diseases, tissue injury, diabetes and regenerative medicine.

Why to Attend?

Breast Pathology 2018 could be an exceptional event that brings along a novel and International mixture of giant and medium pathology outlines. An easily accessible entry point to the understanding of the pathology of breast diseases .Uses the flexibility of the web to allow rapid updating, detail view on Cross-specialty topics such as immunohistochemistry and specimen handling protocols. Diagnosis of breast pathology. Breast pathology 2018 conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising women health and fitness across the world. World-renowned speakers, the most recent research, tactics, and the newest updates in Breast Pathology fields are hallmarks of this conference.

Target Audience:

Women’s Healthcare professors, researchers, nurses, Directors/Co-directors & Medical Oncologists, Surgical Oncologists, Radiation Oncologists, Surgeons, Gynaecologists, Pathologists, epidemiologists, Breast cancer Nurses, Medical staff & Medical Journalists, Cancer centre Managers, Vice Presidents/ Directors & Brand Manufacturers/ Marketers of screening instrumental Products. Professors, researchers and Students from Academia in the study of Women’s health filed. other healthcare professionals interested in the latest advances and techniques in the field. Trainees in breast pathology, Teachers seeking educational material, the wider public. Another segment of target audience is Pharmaceutical researchers, Clinical organizations, Educational institutes.

Major breast cancer hospitals in Vancouver

BC Cancer Agency
Vancouver Prostate Centre
LEMMO Integrated Cancer Care Inc.
InspireHealth Supportive Cancer Care
Vancouver General Hospital
British Columbia Children's Hospital
A+ cancer healing clinic wonmp education professor weston reserve university
Yaletown Naturopathic Clinic
Vancouver Coastal Health
Fraser Valley Centre
Dr. David B. Dix

Major Women’s Health and Breast Cancer Associations around the Globe

Society for Women's Health Research
European Association for Cancer Research (EACR)
American Cancer Society.
Spanish Association for Cancer Research (CMA)
Association of Women's Health, Obstetric and Neonatal Nurses
New Zealand Breast Cancer Foundation (NZBCF)
International Association for Women's Mental Health
Association of Chartered Physiotherapists in Women’s Health
American Medical Women's Association
Caribbean Women's Health Association

Top universities in Canada

The University of British Columbia
University of Alberta
York University
University of Waterloo
University of Ottawa
University of Calgary
Ryerson University
Queen's University
McMaster University
University de Montréal
University of Western Ontario
University of Manitoba
Simon Fraser University
University of Guelph
Carleton University
University du Québec à Montréal
Concordia University
George Brown College
Dalhousie University
University of Victoria
Sheridan College
Algonquin College
MacEwan University
Brock University
Mount Royal University
Thompson Rivers University
University of Saskatchewan
University of Regina
Memorial University of Newfoundland
Athabasca University
University of Windsor
Wilfrid Laurier University

Top Breast Cancer Drugs Sales in 2014

Sales of breast cancer treatments are set to increase by an average of 5.8% a year in nine major markets, increasing from a value of $9.8 billion in 2013 to $18.2 billion by 2023, according to new forecasts from IMS Health.

Past Conference Report

Breast Pathology 2017

Breast Pathology 2017 is got successfully held in Toronto, Canada on August 23 - 24, 2017 at Holiday Inn Toronto International Airport. It was good conference with provoking speakers from all over the world with amazing presentations suits the theme: “Think pink! Myriad advancing women health & transfiguring women’s lives” along with industrial exhibitions!

Keynotes

Shahla Masood
University of Florida, USA

Namsun Paik
Ewha Womans Cancer Center Hospital for Women, Korea

Myron R Szewczuk
Queen’s University, Canada

Session Chair: Shahla Masood, University of Florida, USA
Session Chair: Namsun Paik, Ewha Womans Cancer Center Hospital for Women, South Korea
Session Co-chair: R M Kappel, Dr. Kappel Institute, Netherlands

Session Chair: Myron R Szewczuk, Queen’s University, Canada
Session Co-chair: Sveta Silverman, University of Alberta, Canada

Past Reports Gallery

To Collaborate Scientific Professionals around the World

Conference Date July 25-26, 2018

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

Breast Pathology 2017 Conference

Supported By

Breast Cancer: Current Research

Journal of Cancer Science & Therapy

Journal of Clinical & Experimental Pathology

Journal of Cancer Diagnosis

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by

Breast Pathology and Cancer Diagnosis

July 25-26, 2018 Vancouver, Canada

Theme: Understanding current Research to obtain best results in Breast Pathology

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Recommended Global Pathology Conferences

USA & Americas

Europe & UK

Asia Pacific & Middle East

Breast Pathology & Cancer Congress

Breast Pathology 2018

Breast Pathology Sessions

Market Projection

Past Conference Report

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By

Media partners & Collaborators & Sponsors

2018			2019
May	June	July	March
August	September	October	April
November	December